Wall Street deal maker Ronald E. Blaylock has just made his first investment in Pfizer stock three years after he joined the board — signalling there is about to be an upward move in the company’s fortunes.
The Corporate Governance insider, who sits on the Audit Committee, snapped up $500k shares just three weeks ago ahead of the hotly anticipated Q4 $195bn Mylan and Upjohn mega-merger-Spinoff called Viatris — as well as the Cerevel Therapeutics Nasdaq IPO.